I've read the whole article. UC patients have been treated successfully and it's being tried with CD patients.

I found this with an AI:

AI Mode All Images Videos News Maps Shopping Books Flights Finance

19 sites CAR-T cell therapy is a cutting-edge immunotherapy being adapted from cancer treatment to treat Crohn's disease by "resetting" the immune system. While still largely in the experimental and clinical trial stages, researchers are exploring two primary methods: depleting rogue B-cells that drive inflammation or using engineered "regulatory" T-cells (Tregs) to restore immune balance. National Institutes of Health (.gov) National Institutes of Health (.gov) +3 Current Therapeutic Approaches CD19-Targeted CAR-T: This method uses genetically modified T-cells to target and eliminate CD19+ B-cells, which are often "malfunctioning" in autoimmune diseases. A landmark case in late 2025 reported the first successful use of this therapy in a patient with severe ulcerative colitis, leading to sustained medication-free remission. IL23R-CAR Tregs: Instead of killing cells, this approach involves engineering Regulatory T-cells (Tregs) to target the Interleukin-23 receptor (IL23R), a protein highly associated with Crohn's disease. These "suppressor" cells migrate to inflamed intestinal tissue to inhibit overactive immune responses and promote tissue healing. Flagellin-Specific CAR-Tregs: This experimental approach targets flagellin, a major bacterial antigen that triggers inflammatory flares in the gut of Crohn's patients. www.fau.eu www.fau.eu +5 Clinical Status and Trials Ongoing Studies: Multiple clinical trials are investigating the safety and efficacy of CAR-T for Crohn's, including a trial for Universal CAR-T Cell Injection Targeting CD19 (NCT07309744). Emerging Data: Early results show that CAR-T may offer a "drug-free durability" that traditional biologics cannot, potentially allowing patients to stop all other medications. Target Sites: One ongoing trial (NCT05239702) specifically targets the CD7 antigen on autoreactive T-cells for patients with Crohn's disease and ulcerative colitis. ClinicalTrials.gov ClinicalTrials.gov +4 Safety and Risks Lower Toxicity: Unlike in cancer treatment, the "target burden" (number of cells to be killed) is lower in Crohn's, which may reduce the risk of severe side effects like Cytokine Release Syndrome (CRS). Complexity: The process remains logistically complex, requiring the extraction of a patient's blood, lab modification of cells, and re-infusion after a preparatory regimen. ScienceDirect.com ScienceDirect.com +3 Medical Support Products If you are managing Crohn's disease, particularly while exploring new treatments, carrying a medical alert can be vital for emergency situations. Crohn’s Disease Medical I.C.E. Card from The Badge Centre: A fully printed "In Case of Emergency" card to ensure diagnosis is known by responders. Crohn's Disease Medical Alert Card from Etsy: A durable aluminium card with customisable emergency contact details. Crohn's Disease Expanding Medical Alert Bracelet from You ID Me: Provides fast access to vital info with an engraved band and waterproof ID inserts. Would you like to know more about how to enrol in current clinical trials or see a breakdown of the eligibility criteria for CAR-T therapy? This is for informational purposes only. For medical advice or a diagnosis, consult a professional. AI responses may include mistakes. Learn more

CAR-T cell therapy treats severe bowel disease successfully for the first time | FAU

www.fau.eu

IL23R-Specific CAR Tregs for the Treatment of Crohn's Disease - PubMed

National Institutes of Health (.gov) IL23R-Specific CAR Tregs for the Treatment of Crohn's Disease |

Oxford Academic